Stocktoria
Natera, Inc. NTRA
Nasdaq · XNAS · stock · Services-Medical Laboratories · website · IPO 2015-07-02
Natera, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -13.4% | -13.1% | -41.2% | -66.0% | -74.8% |
| Net margin | -9.0% | -11.2% | -40.2% | -66.8% | -75.4% |
| FCF margin | 4.7% | 4.1% | -26.4% | -58.4% | -60.2% |
| Return on assets | -8.7% | -11.5% | -30.2% | -39.3% | -38.1% |
| Return on equity | -12.2% | -15.9% | -56.8% | -77.6% | -72.2% |
| Debt / equity | — | — | 0.37× | 0.40× | 0.43× |
| Current ratio | 3.39 | 4.00 | 4.10 | 3.90 | 4.99 |
| Revenue growth | 35.9% | 56.7% | 32.0% | 31.1% | 60.0% |
Source: SEC EDGAR filings · CIK 0001604821 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.